We're placing Barr Pharmaceuticals BRL under review while we evaluate the company's decision, announced Tuesday, to acquire Pliva. Barr is paying $2.2 billion in cash for the Croatia-based generic drug firm. The transaction geographically diversifies Barr's primarily U.S.-based operations, as 78% ...
Plus, a top executive bolts from eBay, Brazilian telcos get cheap, and more.
Nick Kaiser's Amana funds, which invest according to Islamic law, are trouncing their large-cap competition.